Impact of hepatitis B core antibody (anti HBc) seropositivity on interferon/ribavirin treatment response in patients with chronic hepatitis C

AntiHBc seropositivity among patients with chronic HCV infection is not a rare entity (57.14 %). We observed that antiHBc antibody seropositivity does not have a significant impact on treatment responses to interferon/ribavirin therapy in patients for chronic HCV infection in contrast to some report...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Bratislavské lékarské listy 2007, Vol.108 (2), p.65-69
Hauptverfasser:	Biyikoglu, Ibrahim, Filik, Levent, Oguz, Dilek, Cicek, Bahattin, Yilmaz, Birhan, Altiparmak, Emin
Format:	Artikel
Sprache:	eng
Schlagworte:	Antiviral Agents - administration & dosage Drug Therapy, Combination Female Hepatitis B Antibodies - blood Hepatitis C, Chronic - drug therapy Hepatitis C, Chronic - immunology Humans Interferon-alpha - administration & dosage Male Middle Aged Recombinant Proteins Ribavirin - administration & dosage
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	AntiHBc seropositivity among patients with chronic HCV infection is not a rare entity (57.14 %). We observed that antiHBc antibody seropositivity does not have a significant impact on treatment responses to interferon/ribavirin therapy in patients for chronic HCV infection in contrast to some reports in the literature (Tab. 6, Ref. 39) Full Text (Free, PDF) www.bmj.sk.
ISSN:	0006-9248